-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Anxiety Provoking Consultations: Mast Cells and Eosinophils

Program: Education Program
Hematology Disease Topics & Pathways:
Biological therapies, adult, Diversity, Equity, and Inclusion (DEI) , Other Pathogens, drug development, Chronic Myeloid Malignancies, pediatric, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Saturday, December 10, 2022: 4:00 PM-5:15 PM
295-296 (Ernest N. Morial Convention Center)

Description:
Dr. Cem Akin will discuss various clinical presentations and referral scenarios for mast cell disorders in the hematology practice, and when and how to initiate further diagnostic workup and how to interpret the results. He will review differential diagnosis of a patient with elevated tryptase level including hereditary alpha tryptasemia, and mastocytosis. He will discuss treatment options for mast cell activation symptoms including new tyrosine kinase inhibitors in indolent systemic mastocytosis.

Dr. Amy Klion will review the differential diagnosis of marked eosinophilia and classification of hypereosinophilic syndromes.  She will provide a general approach to treatment of patients with idiopathic and lymphocyte-driven hypereosinophilic syndromes, focusing on eosinophil-targeted biologics. Lastly, Dr. Klion will briefly discuss the potential risks of eosinophil depletion.

Dr. Jason Gotlib will navigate the treatment of advanced systemic mastocytosis (AdvSM) and primary eosinophilic neoplasms including chronic eosinophilic leukemia (CEL) and myeloid/lymphoid neoplasms with fusion tyrosine kinases (MLN-eo).  He will review the latest data and future directions of using KIT inhibition in AdvSM, with an emphasis on the challenge of SM with an associated hematologic neoplasm.  Lastly, Dr. Gotlib will survey the molecular landscape of primary eosinophilic neoplasms and opportunities for targeted therapy, including tyrosine kinase inhibitors in MLN-eo with rearranged PDGFRA/B, FGFR1, JAK2, FLT3, and ABL1.

Chair:
Jason Gotlib, MD, MS, Stanford Cancer Center
Disclosures:
Gotlib: Cogent Biosciences: Consultancy, Research Funding; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; PharmaEssentia: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kartos: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Deciphera: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Blueprint Medicines Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Allakos: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.
Dr. Cem Akin will discuss various clinical presentations and referral scenarios for mast cell disorders in the hematology practice, and when and how to initiate further diagnostic workup and how to interpret the results. He will review differential diagnosis of a patient with elevated tryptase level including hereditary alpha tryptasemia, and mastocytosis. He will discuss treatment options for mast cell activation symptoms including new tyrosine kinase inhibitors in indolent systemic mastocytosis.

Dr. Amy Klion will review the differential diagnosis of marked eosinophilia and classification of hypereosinophilic syndromes.  She will provide a general approach to treatment of patients with idiopathic and lymphocyte-driven hypereosinophilic syndromes, focusing on eosinophil-targeted biologics. Lastly, Dr. Klion will briefly discuss the potential risks of eosinophil depletion.

Dr. Jason Gotlib will navigate the treatment of advanced systemic mastocytosis (AdvSM) and primary eosinophilic neoplasms including chronic eosinophilic leukemia (CEL) and myeloid/lymphoid neoplasms with fusion tyrosine kinases (MLN-eo).  He will review the latest data and future directions of using KIT inhibition in AdvSM, with an emphasis on the challenge of SM with an associated hematologic neoplasm.  Lastly, Dr. Gotlib will survey the molecular landscape of primary eosinophilic neoplasms and opportunities for targeted therapy, including tyrosine kinase inhibitors in MLN-eo with rearranged PDGFRA/B, FGFR1, JAK2, FLT3, and ABL1.

How to Evaluate the Patient with a Suspected Mast Cell Disorder and How/When to Manage Symptoms

Cem Akin, MD, PhD

University of Michigan, Ann Arbor, MI
How to Evaluate the Patient with a Suspected Eosinophil Disorder and How/When to Manage Symptoms

Amy D Klion, MD

NIAID, National Institutes of Health, Bethesda, MD
Available and Emerging Therapies for Bona Fide Advanced Systemic Mastocytosis and Primary Eosinophilic Neoplasms

Jason Gotlib, MD, MS

Stanford Cancer Center, Stanford, CA
See more of: Education Program
<< Previous Session | Next Session >>